Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson.
Precision medicine is an emerging approach to the diagnosis and treatment of disease which is tailored to the individual characteristics of each patient. It relies on the classification of individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology or prognosis of disease, or in their response to a specific treatment. The advent of cheap genome sequencing and ‘big data’ analysis brings unprecedented opportunity for the development of patient-targeted diagnostics and therapies based on genetic profiles.
This year, the UK’s ambitious 100,000 Genomes Project is expected to be completed, focusing on patients with cancer or rare diseases. In addition, the US 21st Century Cures Act of 2016 includes provisions that will advance precision medicine, including the Precision Medicine Initiative, which will review the genetic data of no fewer than one million Americans. Allied to this, a Cancer Moonshot initiative aims to ‘eliminate cancer as we know it’.
While public funding for precision medicine seems to be in the ascendancy, a key question is whether IP or regulatory regimes create commercial incentives and what can be done now to capture IP value.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Potter Clarkson, Precision medicine, Sheena Linehan . , treatment, patent, precision, medicine, dMMR, therapeutics, MSI-H, patenting, diagnosis, tumours